Samer Al Hadidi/LinkedIn
Dec 10, 2024, 07:06
Samer Al Hadidi: Discontinuation of Lenalidomide Maintenance after ASCT in MM
Samer Al Hadidi, Assistant Professor at UAMS Myeloma Center, shared a post on X:
“Oral myeloma: sustained MRD Negativity for Three Years Can Guide Discontinuation of Lenalidomide Maintenance after ASCT in Multiple Myeloma: Results from a Prospective Cohort Study.
Important study – stopping therapy with sustained MRD -ve for 3 years is possible for patients (we do that in UAMS Myeloma Center).
23% converted to MRD +ve and only 8% actually had progression after 3 years of follow-up.
We should all do finite therapy especially for standard risk myeloma.”
More posts featuring Samer Al Hadidi.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22